Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.74 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | BRS3 | P32247 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13666464 | 0.85 | CYP19A1 (1.00) | CYP19A1NOTUMCYP2D6CYP2C9CYP1A2 | |
| SCHEMBL13526927 | 0.80 | CYP19A1 (0.74) | CYP19A1NOTUMCYP2D6CYP2C9CYP1A2 | |
| SCHEMBL13666599 | 0.79 | CYP19A1 (0.77) | CYP19A1NOTUMCYP3A4BRS3 | |
| SCHEMBL21156935 | 0.78 | NOTUM (0.54) | CYP19A1NOTUMBRS3KDM5B | |
| SCHEMBL21156458 | 0.74 | CYP2D6 (0.74) | CYP19A1CYP2D6CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL21157730 | 0.73 | NOTUM (0.67) | NOTUM | |
| SCHEMBL28166936 | 0.73 | NOTUM (0.67) | CYP19A1NOTUMCYP2C9CYP1A2 | |
| SCHEMBL17297776 | 0.72 | NOTUM (0.62) | CYP19A1NOTUMBRS3KDM5B | |
| SCHEMBL10447781 | 0.72 | NOTUM (0.78) | CYP19A1NOTUMBRS3 | |
| SCHEMBL29084891 | 0.72 | NOTUM (0.65) | CYP19A1NOTUMCYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | CYP19A1 709/4885NOTUM 3719/4885CYP2D6 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.